Teng-Yeow Tan1, Yeh-Lin Kuo, Wei-Che Lin, Ting-Yao Chen. 1. Dept. of Neurology, Section of Cerebrovascular Disease, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Chang Gung University College of Medicine, 123, Ta-Pei Road, Niao-Sung Hsiang, Kaohsiung County 833, Taiwan. tengyeowtan@yahoo.com
Abstract
OBJECTIVES: Intracranial arterial stenosis (IAS) is a severe disease with a high recurrent stroke rate even under the best medical treatment. Statins have been demonstrated to prevent stroke and to slow or halt atherosclerosis progression. This study was performed to observe the effect of atorvastatin on the progression of IAS, explore the factors associated with atherosclerosis regression and the recurrent rate of stroke. METHODS: A hospital-base observation study enrolled 40 stroke patients with middle cerebral artery (MCA) or/and basilar artery (BA) stenosis. All participants had hyperlipidemia and were given atorvastatin 40 mg per day for at least six months. IAS was assessed by magnetic resonance angiogram (MRA) at the time of enrollment and then at least six months later. The primary outcome was the progression of IAS. All patients were also given antiplatelet agents for stroke prevention. RESULTS: At the end of the study, 23 (58 %), 15 (38 %) and 2 (4 %) patients had regressed, stationary and progressed IAS, respectively. Females were likely to have regressed IAS. The recurrent stroke rate was 18 %. Among the 54 stenotic vessels, 29 (54 %) vessels were assessed as improvement in stenosis. CONCLUSION: Compared with other studies, more regressed, stationary IAS and less progressed IAS were found in our study. Female gender was likely to have regressed IAS after statin treatment. Further clinical outcome trials are required to assess the effects of such therapy on morbidity and mortality in this particular group of patients.
OBJECTIVES:Intracranial arterial stenosis (IAS) is a severe disease with a high recurrent stroke rate even under the best medical treatment. Statins have been demonstrated to prevent stroke and to slow or halt atherosclerosis progression. This study was performed to observe the effect of atorvastatin on the progression of IAS, explore the factors associated with atherosclerosis regression and the recurrent rate of stroke. METHODS: A hospital-base observation study enrolled 40 strokepatients with middle cerebral artery (MCA) or/and basilar artery (BA) stenosis. All participants had hyperlipidemia and were given atorvastatin 40 mg per day for at least six months. IAS was assessed by magnetic resonance angiogram (MRA) at the time of enrollment and then at least six months later. The primary outcome was the progression of IAS. All patients were also given antiplatelet agents for stroke prevention. RESULTS: At the end of the study, 23 (58 %), 15 (38 %) and 2 (4 %) patients had regressed, stationary and progressed IAS, respectively. Females were likely to have regressed IAS. The recurrent stroke rate was 18 %. Among the 54 stenotic vessels, 29 (54 %) vessels were assessed as improvement in stenosis. CONCLUSION: Compared with other studies, more regressed, stationary IAS and less progressed IAS were found in our study. Female gender was likely to have regressed IAS after statin treatment. Further clinical outcome trials are required to assess the effects of such therapy on morbidity and mortality in this particular group of patients.
Authors: E Feldmann; J L Wilterdink; A Kosinski; M Lynn; M I Chimowitz; J Sarafin; H H Smith; F Nichols; J Rogg; H J Cloft; L Wechsler; J Saver; S R Levine; C Tegeler; R Adams; M Sloan Journal: Neurology Date: 2007-04-04 Impact factor: 9.910
Authors: Allen J Taylor; Steven M Kent; Patrick J Flaherty; Louis C Coyle; Thor T Markwood; Marina N Vernalis Journal: Circulation Date: 2002-10-15 Impact factor: 29.690
Authors: John R Crouse; Joel S Raichlen; Ward A Riley; Gregory W Evans; Mike K Palmer; Daniel H O'Leary; Diederick E Grobbee; Michiel L Bots Journal: JAMA Date: 2007-03-25 Impact factor: 56.272
Authors: E de Groot; J W Jukema; A D Montauban van Swijndregt; A H Zwinderman; R G Ackerstaff; A F van der Steen; N Bom; K I Lie; A V Bruschke Journal: J Am Coll Cardiol Date: 1998-06 Impact factor: 24.094